University of Michigan "Nephrology Research BioBank"



Status:Recruiting
Conditions:Renal Impairment / Chronic Kidney Disease
Therapuetic Areas:Nephrology / Urology
Healthy:No
Age Range:Any
Updated:10/26/2018
Start Date:September 2006
End Date:August 2026
Contact:Chrysta Lienczewsky
Email:boridley@med.umich.edu
Phone:734-764-2924

Use our guide to learn which trials are right for you!

Michigan Nephrology Research BioBank for Molecular Analysis of Renal Disease "Nephrology Research BioBank"

The purpose of the study is to create a Nephrology Tissue Biobank enabling the study of
kidney disease from the perspectives of epidemiology, genetics and molecular biology.

Each year chronic kidney disease (CKD) claims the lives of millions of people worldwide.
Costs for patient care are in excess of 2.4 billion dollars in the US alone. At the moment
most kidney diseases are of unknown etiology, are classified according to a microscopic
description of the kidney tissue obtained on biopsy and are treated with non-specific
therapies.

Each kidney contains millions of filter units called nephrons. The nephron consists of a
glomerulus and a tubule. The glomerulus filters the blood of waste products, while retaining
larger molecules that are required for the body to function properly. The filtered fluid then
passes through the tubule, where salts, acids and water are regulated to keep the body in a
normal metabolic state. After the filtered fluid passes through the tubule it is collected in
the bladder as urine. Diseases, which affect the glomeruli or tubules result in kidney
damage. Once kidney function is lost it is generally not recoverable and the only option for
a patient's survival is dialysis or transplantation.

The purpose of this study is to provide a platform, which will enable researchers with
different areas of expertise, to investigate the molecular markers and pathways of kidney
disease and its progression. Our goal is to increase our understanding of kidney health
issues and to develop new prevention and treatment strategies which will be shared with the
medical community and the public.

Study description:

Individuals seen in the nephrology clinic at the University of Michigan will be eligible to
enroll in this study. Their clinical data will be recorded, blood and urine samples will be
collected and if a biopsy is performed as a part of their standard medical care then a small
sample will be reserved for use in the study after all pathological evaluations required for
patient care are completed. Biological samples will be available for biochemical, molecular
biological and genetic testing and for correlation of these parameters to the individuals
clinical data in future studies.

Significance:

Advances in the understanding of kidney disease may 1) provide methods of early detection of
disease, 2) identify molecular markers that will help physician prescribe the most
appropriate and beneficial treatments, 3) identify targets for the development of new
treatments, and 4) decrease the enormous cost of caring for individuals with CKD.

Aim:

1. Create a biobank enabling the study of kidney disease from the perspectives of
epidemiology, genetics and molecular biology.

2. Create a resource for the study of kidney disease, which will enable the researchers at
the University of Michigan to work collaboratively toward the elucidation of the
molecular pathways, which cause kidney disease.

Inclusion Criteria:

- Men, women and children undergoing kidney and/or pancreas biopsy at the University of
Michigan

Exclusion Criteria:

- Individuals not willing to provide consent (for prospective biopsy)
We found this trial at
1
site
1500 E Medical Center Dr
Ann Arbor, Michigan 48109
(734) 936-4000
Principal Investigator: Matthias Kretzler, MD
Phone: 734-764-2924
University of Michigan Health System The University of Michigan is home to one of the...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials